Altus reacquires rights to ALTU-135
Massachusetts, USA-based Altus Pharmaceuticals has re-acquired development and commercialization rights to ALTU-135 from German drug developer Dr Falk Pharma, which originally licensed the drug in Europe, countries of the former Soviet Union, Israel and Egypt in 2002 (Marketletters passim).
The product, which is intended to improve digestive function in patients suffering from cystic fibrosis, was granted Orphan Drug designation by the European Medicines Agency (EMEA) in July 2004. The announced repurchase includes the transferral of these orphan rights. In exchange, Altus will pay the German firm 12.0 million euros ($16.0 million) over the next three years. In the USA, ALTU-135 has been granted Orphan Drug designation, as well as CMA Pilot 2 status by the Food and Drug Administration. Currently, it is being assessed in pivotal Phase III trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze